Carfilzomib boosted combination therapy for relapsed multiple myeloma

References

• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• ThumallapallyNYuHAstiDVennepureddyATerjanianTSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Onco Targets Ther201694843485827540299
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood200811152516252017975015
   PubMed Web of Science ®Google Scholar
• DimopoulosMARichardsonPGMoreauPAndersonKCCurrent treatment landscape for relapsed and/or refractory multiple myelomaNat Rev Clin Oncol2015121425425421279
   PubMed Web of Science ®Google Scholar
• HoySMCarfilzomib triple combination therapy: a review in relapsed multiple myelomaTarget Oncol201611225526226972294
   PubMedGoogle Scholar
• ManasanchEEKordeNZingoneAThe proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myelomaLeuk Lymphoma20145581707171424261677
   PubMed Web of Science ®Google Scholar
• KortuemKMStewartAKCarfilzomibBlood2013121689389723393020
   PubMed Web of Science ®Google Scholar
• LeeSJLevitskyKParlatiFClinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assayBr J Haematol2016173688489527071340
   PubMedGoogle Scholar
• JakobCEgererKLiebischPCirculating proteasome levels are an independent prognostic factor for survival in multiple myelomaBlood200710952100210517095627
   PubMedGoogle Scholar
• ManasanchEEde LarreaCFZingoneAEnzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasoneLeuk Lymphoma201758363964527687480
   PubMed Web of Science ®Google Scholar
• KordeNRoschewskiMZingoneATreatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in Patients with smoldering or newly diagnosed multiple myelomaJAMA Oncol20151674675426181891
   PubMed Web of Science ®Google Scholar
• HistoryKAKyprolis Approval History Available from: https://www.drugs.com/history/kyprolis.htmlAccessed September 16, 2016
   Google Scholar
• FDAKYPROLIS FDA Prescribing Information Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202714s009lbl.pdfAccessed September 13, 2016
   Google Scholar
• EMAEMA KYPROLIS Information Available from: http://www.ema.europa.eu/docs/en_GB/document_library?EPAR-Product_Information/human/003790/WC500197692.pdfAccessed September 17, 2016
   Google Scholar
• O’ConnorOAStewartAKValloneMA phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignanciesClin Cancer Res200915227085709119903785
   PubMed Web of Science ®Google Scholar
• AlsinaMTrudelSFurmanRRA phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphomaClin Cancer Res201218174830484022761464
   PubMed Web of Science ®Google Scholar
• SiegelDSMartinTWangMA phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myelomaBlood2012120142817282522833546
   PubMed Web of Science ®Google Scholar
• JakubowiakAJSiegelDSMartinTTreatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyLeukemia201327122351235623670297
   PubMed Web of Science ®Google Scholar
• PapadopoulosKPSiegelDSVesoleDHPhase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myelomaJ Clin Oncol201533773273925225420
   PubMed Web of Science ®Google Scholar
• BerensonJRCartmellABessudoACHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaBlood2016127263360336827207788
   PubMed Web of Science ®Google Scholar
• NiesvizkyRMartinTG3rdBensingerWIPhase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaClin Cancer Res20131982248225623447001
   PubMed Web of Science ®Google Scholar
• WangMMartinTBensingerWPhase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaBlood2013122183122312824014245
   PubMed Web of Science ®Google Scholar
• StewartAKRajkumarSVDimopoulosMACarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med2015372214215225482145
   PubMed Web of Science ®Google Scholar
• Avet-LoiseauHFonsecaRSiegelDCarfilzomib significantly improves the progression free survival of high-risk patients in multiple myelomaBlood201612891174118027439911
   PubMed Web of Science ®Google Scholar
• DimopoulosMAMoreauPPalumboACarfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyLancet Oncol2016171273826671818
   PubMed Web of Science ®Google Scholar
• ShahJJStadtmauerEAAbonourRCarfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myelomaBlood2015126202284229026384354
   PubMed Web of Science ®Google Scholar
• San MiguelJWeiselKMoreauPPomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialLancet Oncol201314111055106624007748
   PubMed Web of Science ®Google Scholar
• San-MiguelJFHungriaVTYoonSSOverall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trialLancet Haematol2016311e506e51527751707
   PubMed Web of Science ®Google Scholar
• San-MiguelJFHungriaVTYoonSSPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialLancet Oncol201415111195120625242045
   PubMed Web of Science ®Google Scholar
• VesoleDHBilottiERichterJRPhase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myelomaBr J Haematol20151711525926018491
   PubMed Web of Science ®Google Scholar
• FARYDAK FDA Prescribing information Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf?et_cid=35529885&et_rid=931330620&linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f205353s000lbl.pdfAccessed August 25, 2016
   Google Scholar
• BerdejaJGGregoryTBFaberE4530 a phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma (MM).: final analysis of second dose expansionPresented at: 58th Annual Meeting and ExpositionDecember 3–6 2016San Diego, CAAccessed December 21, 2016
   Google Scholar
• BrownSHinsleySBallesterosMThe MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaBMC hematol2016161427190631
   PubMedGoogle Scholar
• GramatzkiMGüntherAOffidananiMCarfilzomib in combination with bendamustine and dexamethasone (CBd) in relapsed and/or refractory patients with multiple myeloma: the phase I/II EMN09 studyBlood20161283334Accessed December 12, 2016
   Google Scholar
• FialaMAKellerJSekharJ3329 A Phase II Study of carfilzomib, pegylated liposomal doxorubicin, and dexamethasone for relapsed or refractory multiple myelomaPresented at: 58th Annual Meeting and ExpositionDecember 3–6, 2016San Diego, CAAccessed December 21, 2016
   Google Scholar
• ZhangKDesaiAZengDGongTLuPWangMMagic year for multiple myeloma therapeutics: key takeaways from the ASH 2015 Annual MeetingOncotarget2016 Epub20161111
   Google Scholar
• Ameican Society of Hematology973 Final results of phase 1 MMRC trial of selinexor, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma (RRMM) Available from: https://ash.confex.com/ash/2016/webprogram/Paper93704.htmlAccessed December 20, 2016
   Google Scholar
• JakubowiakAJasielecJRosenbaumCAPhase 1 MMRC trial of selinexor, carfilzomib (CFZ), and dexamethasone (DEX) in relapsed and relapsed/refractory multiple myeloma (RRMM)Blood2015126234223
   Google Scholar
• JakubowiakAJDytfeldDGriffithKAA phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaBlood201212091801181922665938
   PubMed Web of Science ®Google Scholar
• Myeloma NGVM Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdfAccessed August 21, 2016
   Google Scholar
• BringhenSPetrucciMTLaroccaACarfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studyBlood20141241636924855212
   PubMed Web of Science ®Google Scholar
• StewartAKDimopoulosMAMassziTHealth-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myelomaJ Clin Oncol2016 Epub201696
   Web of Science ®Google Scholar
• HasinoffBBPatelDWuXMolecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and CarfilzomibCardiovasc Toxicol2016 Epub201677
   Google Scholar
• ChariAHajjeDCase series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoringBMC Cancer20141491525471129
   PubMed Web of Science ®Google Scholar
• FDA Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf?et_cid=29661884&et_rid=463638624&linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f202714lbl.pdf%20(Accessed%20on%20August%2013,%202012Accessed August 15, 2016
   Google Scholar
• AtrashSTullosAPanozzoSCardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomibBlood Cancer J20155e27225594159
   PubMed Web of Science ®Google Scholar
• MikhaelJManagement of carfilzomib-associated cardiac adverse eventsClin Lymphoma Myeloma Leuk201616524124526907720
   PubMed Web of Science ®Google Scholar
• HajekRMassziTPetrucciMTA randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)Leukemia201631110711427416912
   PubMedGoogle Scholar
• LonialSWeissBMUsmaniSZDaratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trialLancet2016387100271551156026778538
   PubMed Web of Science ®Google Scholar
• PlesnerTArkenauHTGimsingPPhase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaBlood2016 Epub2016816
   Web of Science ®Google Scholar
• PalumboAChanan-KhanAWeiselKDaratumumab, Bortezomib, and Dexamethasone for multiple myelomaN Engl J Med2016375875476627557302
   PubMed Web of Science ®Google Scholar
• FDA Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf?et_cid=37060330&et_rid=931330620&linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f761035s000lbl.pdfAccessed August 18, 2016
   Google Scholar
• LonialSDimopoulosMPalumboAElotuzumab therapy for relapsed or refractory multiple myelomaN Engl J Med2015373762163126035255
   PubMed Web of Science ®Google Scholar
• BazRCMartinTG3rdLinHYRandomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myelomaBlood2016127212561256826932802
   PubMed Web of Science ®Google Scholar
• MoreauPMassziTGrzaskoNOral ixazomib, lenalidomide, and dexamethasone for multiple myelomaN Engl J Med2016374171621163427119237
   PubMed Web of Science ®Google Scholar
• KrishnanAKapoorPPalmerJ3316 A phase I/II trial of ixazomib (Ix), pomalidomide (POM), and dexamethasone (DEX), in relapsed/refractory (R/R) multiple myeloma (MM) patients: responses in double/triple refractory myeloma and poor risk cytogeneticsAccessed December 12, 2016
   Google Scholar
• KumarSGrzaskoNDelimpasiS3327 Phase 2 study of the all-oral combination of ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)Accessed December 12, 2016
   Google Scholar
• PozziSGentileMSacchiSBendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II studyLeuk Lymphoma201618
   Google Scholar
• LiuLZhaoNXuWShengZWangLPooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myelomaJ Hematol Oncol2016915427405295
   PubMedGoogle Scholar
• GonsalvesWIMilaniPDerudasDBuadiFKThe next generation of novel therapies for the management of relapsed multiple myelomaFuture Oncol2017131637527513456
   PubMedGoogle Scholar
• InfanteJRMendelsonDSBurrisHA3rdA first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsInvest New Drugs201634221622426924128
   PubMed Web of Science ®Google Scholar
• GhobrialMDIreneMKaufmanJLClinical Profile of Single-Agent Modified-Release Oprozomib Tablets in Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 StudyASH 2013 Annual Meeting Abstract 3184December 8; 2013Washington, DC
   Google Scholar
• ShahJNiesvizkyRStadtmauerEPomalidomide, and Dexamethasone (OPomd) in patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): initial results of a phase 1b studyBlood20151262337825943787
   PubMedGoogle Scholar
• RichardsonPGZimmermanTMHofmeisterCCPhase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 part 1Blood2016127222693270027009059
   PubMed Web of Science ®Google Scholar
• HoyosVBorrelloIThe immunotherapy era of myeloma: monoclonal antibodies, vaccines and adoptive T cell therapiesBlood2016128131679168727506540
   PubMed Web of Science ®Google Scholar
• MartinTRichterJVijRA dose finding phase II trial of isatuximab (SAR650984, Anti-CD38 mAb) as a single agent in relapsed/refractory multiple myelomaBlood2015126509
   Web of Science ®Google Scholar
• VijRLendvaiNMartinTA phase Ib trial of isatuximab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: interim results from 2 new dose cohortsJCO2016342016
   Google Scholar
• San MiguelJMateosMVShahJPembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Keynote-023Blood2015126505
   Google Scholar
• GarfallALMausMVHwangWTChimeric antigen receptor T cells against CD19 for multiple myelomaN Engl J Med2015373111040104726352815
   PubMed Web of Science ®Google Scholar
• AliSAShiVMaricIT cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myelomaBlood2016128131688170027412889
   PubMed Web of Science ®Google Scholar
• ZouJChenDZongYImmunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myelomaCancer Sci2015106551252125664501
   PubMedGoogle Scholar
• MartinTGMannisGNChariAMunsterPCampanaFHuiA-MPhase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple MyelomaBlood201612822211127789435
   PubMed Web of Science ®Google Scholar
• PlesnerTArkenauH-TGimsingPDaratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)Blood2015126507 Abstract 0507
   Google Scholar